Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat…
$16.24+0.37%
报价 2026-11-13
市值
$2.25B
EV
$5.16B
PE (TTM)
–
预期 PE (FY2026)
7.1x
52 周区间距高点 -4.2%
$9.25$16.95
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
电话会信号
辅助标签Q3 20262026-11-04
下调/撤回指引
指引 下调
信心 3
分析师 4
“We are gaining share on both sides of the Atlantic, and e-commerce is driving further improvement.”
原文引用(1)
- 下调/撤回指引:we have updated our 2026 outlook to reflect the infant formula divestment, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe
蓝色标签在暴涨研究中略有区分度;悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - Specialty & Generic| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PRGOPerrigo Company plc | $2.25B | +0.4% | -6.0% | 30.7% | – | – | 12.9x | |
| BHCBausch Health Companies Inc. | $3.13B | +1.2% | +6.8% | 75% | – | 8.9x | 1.7x | |
| HCMHutchison China Ltd. | $2.6B | +0.3% | +12.2% | 17% | 145.0x | – | 234.4x | |
| RGCRegencell Bioscience Holdings Limited | $2.45B | -3.6% | – | 0% | – | – | – | |
| TRLVTrulieve Cannabis Corp. | $1.86B | -2.2% | -13.8% | 59.9% | – | 6.8x | 8.2x | |
| SUPNSupernus Pharmaceuticals, Inc. | $1.73B | +1.8% | +26.8% | 85.7% | 8.0x | 3.4x | 55.3x | Cheap GARP |
| ANIPANI Pharmaceuticals, Inc. | $1.62B | +0.5% | +26.6% | 61.6% | 13.7x | 5.6x | 9.2x | Cheap GARP |
| ALVOAlvotech | $1.5B | -10.3% | +3.0% | 50.7% | – | – | – | |
| PAHCPhibro Animal Health Corporation | $1.46B | +1.4% | +5.5% | 33.2% | 13.5x | 8.6x | 67.4x | |
| 同行中位数 | – | – | +6.8% | 55.3% | 13.6x | 6.8x | 32.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-27 Q2 2026 | 2026-03-28 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-27 Q3 2025 | 2025-06-28 Q2 2025 | 2025-03-29 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-28 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.02B | $969.2M | $1.11B | $1.04B | $1.06B | $1.04B | $1.14B | $1.09B |
| Gross Margin | 30.7% | 33.6% | 32.6% | 36.1% | 34.4% | 37.6% | 33.9% | 37.2% |
| Operating Margin | 2.3% | 3.5% | 7.6% | 7% | 4.3% | 4.5% | 10% | 7.4% |
| Net Income | $74.5M | $-398.6M | $-1.42B | $7.5M | $-8.4M | $-6.4M | $-44.5M | $-21M |
| Diluted EPS | 0.53 | -2.87 | -10.23 | 0.05 | -0.06 | -0.05 | -0.32 | -0.15 |
| Operating Cash Flow | $138.3M | $-113.6M | $175.4M | $51.7M | $75.9M | $-64.5M | $312.6M | $42.2M |